dc.contributor | Galindo Pedraza, Javier Leonardo | |
dc.contributor | Baldion Elorza, Ana Margarita | |
dc.creator | Suárez Zamora, David Alfonso | |
dc.date.accessioned | 2019-10-02T19:59:42Z | |
dc.date.accessioned | 2022-09-22T15:11:23Z | |
dc.date.available | 2019-10-02T19:59:42Z | |
dc.date.available | 2022-09-22T15:11:23Z | |
dc.date.created | 2019-10-02T19:59:42Z | |
dc.identifier | https://repository.urosario.edu.co/handle/10336/20380 | |
dc.identifier | https://doi.org/10.48713/10336_20380 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3445825 | |
dc.description.abstract | Cancer patients have an increased risk of reactivation of latent tuberculosis infection, it is unknown which strategy on screening should be used in this population in developing countries. We aimed to determine the concordance between the tuberculin skin test and QuantiFERON-TB assay in order to diagnose latent tuberculosis infection in cancer patients. We conducted a cross-sectional study of agreement of diagnostic tests. Prevalence and agreement between tests were calculated. A logistic regression to assess predictors of discordance was performed. The accuracy of the tuberculin skin test to predict QuantiFERON-TB results by ROC curve was evaluated. We included 149 adults with cancer without active tuberculosis. Prevalence of latent tuberculosis infection was 21.5% (n=32), defined as positive results on either test. Tests agreement was moderate for the diagnosis of latent tuberculosis infection (κ=0.43, 90% CI 0.26-0.6). No predictor was associated with the chance of discordant results. Agreement improved slightly using a cut-off point ≥8 mm (κ=0.5, 90% CI 0.35-0.66). In moderate-incidence setting, a moderate agreement was found between tests in cancer patients. Modification of cut-off points of test results achieve marginally better agreement between TST and QFT. | |
dc.language | eng | |
dc.publisher | Universidad del Rosario | |
dc.publisher | Facultad de medicina | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Abierto (Texto Completo) | |
dc.rights | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma.
PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.
EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización.
--------------------------------------
POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | |
dc.source | 1. World Health Organization (WHO). Global tuberculosis report. 2018. Available from: https://www.who.int/tb/publications/global_report/en/. Date last accessed: November 26, 2018 | |
dc.source | 2. Menzies NA, Wolf E, Connors D, et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect Dis. 2018;18:e228-e238. | |
dc.source | 3. Sester M, van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190:1168-1176. | |
dc.source | 4. Cheng MP, Abou Chakra CN, Yansouni CP, et al. Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:635-644. | |
dc.source | 5. Dobler CC, Cheung K, Nguyen J, et al. Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J. 2017;50:pii:1700157. | |
dc.source | 6. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33:956-973. | |
dc.source | 7. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis. 1993;17:968-975. | |
dc.source | 8. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S247. | |
dc.source | 9. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3-20. | |
dc.source | 10. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011;37:88-99. | |
dc.source | 11. Redelman-Sidi G, Sepkowitz KA. IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188:422-431. | |
dc.source | 12. Moon SM, Lee SO, Choi SH, et al. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis. 2013;15:104-109. | |
dc.source | 13. Richeldi L, Losi M, D’Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest. 2009;136:198-204. | |
dc.source | 14. Mohammad HA, Esmail MA, Abdelftah MT, et al. Comparison of the 2-step tuberculin skin test and QuantiFERON-TB Gold in-Tube test in the screening of latent tuberculosis infection in cancer patients. Egypt J Chest Dis Tuberc. 2015;64:681-688. | |
dc.source | 15. Cantor AB. Sample-size calculations for Cohen’s kappa. Psychol Methods. 1996;1:150-153. | |
dc.source | 16. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174. | |
dc.source | 17. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J. 2006;28:31-34. | |
dc.source | 18. Stefan DC, Dippenaar A, Detjen AK, et al. Interferon-gamma release assays for the detection of Mycobacterium tuberculosis infection in children with cancer. Int J Tuberc Lung Dis. 2010;14:689-694. | |
dc.source | 19. Pai M, Dheda K, Cunningham J, et al. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis. 2007;7:428-438. | |
dc.source | 20. Ghassemieh BJ, Attia EF, Koelle DM, et al. Latent tuberculosis infection test agreement in the National Health and Nutrition Examination Survey. Am J Respir Crit Care Med. 2016;194:493-500. | |
dc.source | 21. Detjen AK, Loebenberg L, Grewal HMS, et al. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol. 2009;16:1170-1175. | |
dc.source | 22. Tagmouti S, Slater M, Benedetti A, et al. Reproducibility of interferon gamma (IFN-γ) release assays. A systematic review. Ann Am Thorac Soc. 2014;11:1267-1276. | |
dc.source | 23. Nemes E, Rozot V, Geldenhuys H, et al. Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis infection. Am J Respir Crit Care Med. 2017;196:638-648. | |
dc.source | 24. Winje BA, White R, Syre H, et al. Stratification by interferon-γ release assay level predicts risk of incident TB. Thorax. 2018;73:652-661. | |
dc.source | 25. Barcellini L, Borroni E, Brown J, et al. First independent evaluation of QuantiFERONTB Plus performance. Eur Respir J. 2016;47:1587-1590. | |
dc.source | 26. Barcellini L, Borroni E, Brown J, et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J. 2016;48:1411-1419. | |
dc.source | 27. Hoffmann H, Avsar K, Göres R, et al. Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect. 2016;22:701-703. | |
dc.source | 28. Knierer J, Gallegos Morales EN, Schablon A, et al. QFT-Plus: a plus in variability? Evaluation of new generation IGRA in serial testing of students with a migration background in Germany. J Occup Med Toxicol. 2017;12:1. | |
dc.source | 29. Rueda ZV, Arroyave L, Marin D, et al. High prevalence and risk factors associated with latent tuberculous infection in two Colombian prisons. Int J Tuberc Lung Dis. 2014;18:1166-1171. | |
dc.source | 30. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:45-55. | |
dc.source | 31. World Health Organization (WHO). Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. Available from: http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/. Date last accessed: October 26, 2018. | |
dc.source | 32. World Health Organization (WHO). Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. 2011. Available from: https://www.who.int/tb/publications/tb-igras-statement/en/. Date last accessed: June 14, 2018. | |
dc.source | 33. Zwerling A, Behr MA, Verma A, et al. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8:e1001012. | |
dc.source | 34. Ministerio de Salud y Protección Social. SAPS - Sistema de seguimiento a la estrategia de Atención Primaria en Salud APS. 2014. Available from: http://www.sispro.gov.co/Pages/Observatorios/aps.aspx. Date last accessed: August 12, 2018. | |
dc.source | 35. Singhania A, Wilkinson RJ, Rodrigue M, et al. The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis. Nat Immunol. 2018;19:1159-1168. | |
dc.source | instname:Universidad del Rosario | |
dc.source | reponame:Repositorio Institucional EdocUR | |
dc.subject | Neoplasias | |
dc.subject | Prueba de Tuberculina | |
dc.subject | Ensayos de liberación de interferón gamma | |
dc.subject | Países en desarrollo | |
dc.title | Comparison of the QuantiFERON-TB and tuberculin skin test for detection of latent tuberculosis infection in cancer patients of a developing country | |
dc.type | bachelorThesis | |